An interventional study of Rivaroxaban 15mg and Aspirin 100mg in Atrial Fibrillation, sponsored by Xijing Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-07-27.
Sponsored by Xijing Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 45 studies testing rivaroxaban in Atrial Fibrillation — 8 open to participants now, 9 under way, none of them phase 3. Rivaroxaban · Atrial Fibrillation.
Among the 45 studies testing rivaroxaban in Atrial Fibrillation, this one is the 6th largest by planned enrollment, is one of 4 that started in 2023, is one of 4 with no phase, and was the 40th registered.
4,018 studies on the registry are indexed under Atrial Fibrillation; 965 are open to participants now.
Browse Atrial Fibrillation studies →8 of the 45 studies testing rivaroxaban in Atrial Fibrillation are open now, in 4 countries. Recruiting first, the newest first:
VA Office of Research and Development · Sites in United States
Ages 22+
China National Center for Cardiovascular Diseases · Sites in China
Ages 70+
Seoul National University Hospital · Sites in Korea, Republic of
Ages 19–89
Korea University Anam Hospital · Sites in Korea, Republic of
Ages 19–99
Ottawa Hospital Research Institute · Sites in Canada
Ages 18+
By country, each count listing its studies:
Rivaroxaban: first FDA approval 2011 (XARELTO), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 613 Atrial Fibrillation studies recruiting now, 410 (67%) set no upper age limit and 44 (7%) stop at 75 or younger; 21 take children under 18; 43 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
45 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 4 · Phase 3 17 · Phase 4 19
First in 2004; this study’s year is marked. 4 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 4,220 is above the median of 150 across 2,480 interventional studies indexed under Atrial Fibrillation.
Median enrollment 150 across the 45 interventional studies. Of the 26 that completed or were terminated, 7 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 45 have an industry lead sponsor. The 10 most frequent:
Xijing Hospital is the lead sponsor of 475 studies on the registry; 158 are open to participants now.
Xijing Hospital has 7 studies filed under Atrial Fibrillation — fewer than ten, so there is no comparison to draw.
3 of the studies testing rivaroxaban in Atrial Fibrillation that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06108414China National Center for Cardiovascular DiseasesLow-dose Versus Standard-dose Rivaroxaban in Elderly Patients With Atrial Fibrillation | 2026-12-31 |
| NCT05487950Assistance Publique - Hôpitaux de ParisRivaroxaban Versus Standard of Care for Patients With Excessive Atrial Ectopy or Short Atrial Runs and High Embolism Risk | 2027-04-05 |
| NCT03129490Herlev and Gentofte HospitalThe Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation | 2027-10-30 |
Add all 3 to your calendar (.ics) → With an account.
Among the 45 studies testing rivaroxaban in Atrial Fibrillation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The increased risk of Atrial fibrillation (AF) regarding thromboembolic stroke is predominantly due to the formation and embolization of clots from within the left atrial appendage (LAA). Percutaneous left atrial appendage occlusion (LAAO) is a nonpharmacological strategy for stroke prevention in patients with AF. Data from randomized trials, including PROTECT-AF, PREVAIL, and Prague-17, have suggested that LAAO has comparable efficacy to warfarin or NOACs. Considering these results, LAAO was recommended by the American College of Cardiology (ACC) and European Society of Cardiology (ESC) guidelines as a non-pharmacological stroke prevention strategy for patients with NVAF who have contraindications or are unsuitable for OAC.
The PROTECT-AF and PREVAIL trials stipulated the use of standardized antithrombotic medications which were designed to minimize the risk of stroke, systemic embolism, or device-related thrombosis. This antithrombotic strategy was subsequently endorsed by the guidelines, briefly, patients with LAAO were discharged on warfarin and aspirin for 45 days post-LAAO, if there was no leak or a leak ≤5 mm under transesophageal echocardiography (TEE) at 45-day follow-up, antithrombotic strategies shall switch to dual antiplatelet therapy (DAPT) until 6 months post-LAAO, and then aspirin thereafter.
Although LAAO was recommended by medical societies, previous patient-level meta-analyses have implied that compared with oral anticoagulation, LAAO had significantly more ischemic strokes, suggesting the inability of LAAO to prevent an ischemic stroke from sources beyond LAA. Will a combined strategy of LAAO and OAC further reduce the risk of stroke? The investigators hypothesized that a long-term low dose-Rivaroxaban (10mg daily) post-LAAO might be a potent supplement to the residue risk of ischemic stroke.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HAS-BLED\<3: Rivaroxaban 15 mg QD for 3 months, followed by Rivaroxaban 10 mg QD indefinitely HAS-BLED≥3: Rivaroxaban 10 mg QD for 3 months, followed by Rivaroxaban 2.5 mg bid indefinitely
Drug: Rivaroxaban 15mg · Drug: Rivaroxaban 10mg · Drug: Rivaroxaban 2.5mg
HAS-BLED\<3: Rivaroxaban 15 mg QD + Aspirin 100mg QD for 3 months, then Aspirin 100mg QD indefinitely HAS-BLED≥3: Aspirin 100mg QD + Clopidogrel 75mg QD for 3 months, then Aspirin 100mg QD indefinitely
Drug: Rivaroxaban 15mg · Drug: Aspirin 100mg · Drug: Clopidogrel 75mg
QD
QD
QD
QD
B.I.D
Rate of the composite endpoint of any death, any stroke, systemic embolism, and The Bleeding Academic Research Consortium (BARC)-defined 3 or 5 bleeding events
Time frame: 24 months post randomization
Rate of the composite endpoint of any death, any stroke, systemic embolism, and BARC defined 3 or 5 bleeding events
Time frame: 45 days, 6, 12 months (Time-to-event)
Rate of the composite endpoint of any death, any stroke, systemic embolism
Time frame: 45 days, 6, 12, 24 months (Time-to-event)
Rate of the BARC type 3 or 5 bleeding events
Time frame: 45 days, 6, 12, 24 months (Time-to-event)
Rate of the composite endpoint of any death, any stroke, systemic embolism, myocardial infarction (MI)
Time frame: 45 days, 6, 12, 24 months (Time-to-event)
Rate of any death
Time frame: 45 days, 6, 12, 24 months (Time-to-event)
Rate of any stroke
Time frame: 45 days, 6, 12, 24 months (Time-to-event)
Rate of systemic embolism
Time frame: 45 days, 6, 12, 24 months (Time-to-event)
Rate of myocardial infarction (MI)
Time frame: 45 days, 6, 12, 24 months (Time-to-event)
Rate of BARC type 2, 3 or 5 bleeding events
Time frame: 45 days, 6, 12, 24 months (Time-to-event)
Rate of BARC type 2 bleeding events
Time frame: 45 days, 6, 12, 24 months (Time-to-event)
Rate of BARC type 3 bleeding events
Time frame: 45 days, 6, 12, 24 months (Time-to-event)
Rate of BARC type 5 bleeding events
Time frame: 45 days, 6, 12, 24 months (Time-to-event)
Rate of GUSTO defined major bleeding and/or minor bleeding
Global Use of Strategies to Open Occluded Arteries, (GUSTO) defined major bleeding and/or minor bleeding
Time frame: 45 days, 6, 12, 24 months (Time-to-event)
Rate of TIMI defined major bleeding and/or minor bleeding
Thrombolysis in Myocardial Infarction (TIMI) defined major bleeding and/or minor bleeding
Time frame: 45 days, 6, 12, 24 months (Time-to-event)
Rate of ISTH defined major bleeding and/or clinically relevant minor bleeding
International Society on Thrombosis and Haemostasis (ISTH) defined major bleeding and/or clinically relevant minor bleeding
Time frame: 45 days, 6, 12, 24 months (Time-to-event)
Rate of patient adherence to allocated medication
Adherence is defined as the participant who uses the medication strategies in this trial achieving 80% of the time on the therapeutic range
Time frame: 45 days, 6, 12, 24 months (Binary)
Scores of the National Institutes of Health Stroke Scale (NIHSS) questionnaire
The NIHSS is composed of 11 items, each of which scores a specific ability between a 0 and 4. For each item, a score of 0 typically indicates normal function in that specific ability, while a higher score is indicative of some level of impairment. The individual scores from each item are summed in order to calculate a patient's total NIHSS score. The maximum possible score is 42, with the minimum score being a 0.
Time frame: 45 days, 6, 12, 24 months (Continuous)
Scores of the Modified Rankin Scale (mRS)
The Modified Rankin Score (mRS) is a 6 point disability scale with possible scores ranging from 0 to 5. A separate category of 6 is usually added for patients who expire. The Modified Rankin Score (mRS) is the most widely used outcome measure in stroke clinical trials.
Time frame: 45 days, 6, 12, 24 months (Continuous)
Scores of the 5-level EQ-5D version (EQ-5D-5L) questionnaire
The descriptive system comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions. This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.
Time frame: 45 days, 6, 12, 24 months (Continuous)
Plan to share: No
No publications or documents are linked to this record.
Started Jul 2023 (actual). Primary completion is estimated for Jul 2025, 24 months after the start.
Of 797 non-industry interventional studies with no phase under Atrial Fibrillation, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 59. This study's planned 24 months is below that.
Counting every sponsor, half of 1,052 studies reached it within 33 months; a quarter within 18 and three quarters within 54.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rivaroxaban